PSKCX
Price
$21.68
Change
-$0.07 (-0.32%)
Updated
Sep 18 closing price
Net Assets
331.37M
RPTIX
Price
$97.75
Change
-$0.02 (-0.02%)
Updated
Sep 18 closing price
Net Assets
20.82B
Interact to see
Advertisement

PSKCX vs RPTIX

PSKCX vs RPTIX Comparison Chart in %
View a ticker or compare two or three
VS
PSKCX vs. RPTIX commentary
Sep 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PSKCX is a Buy and RPTIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 20.8B vs. PSKCX (331M). RPTIX pays higher dividends than PSKCX: RPTIX (0.11) vs PSKCX (0.00). PSKCX was incepted earlier than RPTIX: PSKCX (26 years) vs RPTIX (11 years). PSKCX (2.04) is less costly to investors than RPTIX (0.63). RPTIX is a more actively managed with annual turnover of: 31.50 vs. PSKCX (27.00). PSKCX has a lower initial minimum investment than RPTIX: PSKCX (2500) vs RPTIX (500000). RPTIX annual gain was more profitable for investors over the last year : -5.48 vs. PSKCX (-52.31). RPTIX return over 5 years is better than : -23.75 vs. PSKCX (-62.58).
PSKCXRPTIXPSKCX / RPTIX
Total Expense Ratio2.040.63324%
Annual Report Gross Expense Ratio2.040.63324%
Fund Existence26 years11 years-
Gain YTD-11.1110.164-6,777%
Front LoadN/AN/A-
Min. Initial Investment25005000001%
Min. Initial Investment IRAN/AN/A-
Net Assets331M20.8B2%
Annual Yield % from dividends0.000.11-
Returns for 1 year-52.31-5.48955%
Returns for 3 years-44.790.28-15,813%
Returns for 5 years-62.58-23.75264%
Returns for 10 years15.2028.9652%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FTPIX109.670.78
+0.72%
Invesco Technology R5
FDGFX43.450.04
+0.09%
Fidelity Dividend Growth
MLVKX37.76-0.15
-0.40%
BlackRock Advantage Large Cap Val K
SEMCX30.46-0.14
-0.46%
SEI Mid-Cap F (SIMT)
BRSUX16.86-0.08
-0.47%
MFS Blended Research Small Cap Eq R4